Evidence map›Paper›PMID 21860085›Full record

ArticleJournal of Alzheimer's disease : JAD2011

Regional comparison of the neurogenic effects of CNTF-derived peptides and cerebrolysin in AβPP transgenic mice.

Edward Rockenstein, Kiren Ubhi, Edith Doppler, Philipp Novak, Herbert Moessler, Bin Li, Julie Blanchard, Inge Grundke-Iqbal, Khalid Iqbal, Michael Mante and 3 more

RetractedAbstract readRetracted Publication
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Neuroprotection and Non-Invasive Brain Stimulation: Facts or Fiction?International journal of molecular sciences · 2022
    Review
  3. Review
  4. Peptides Derived from Growth Factors to Treat Alzheimer's Disease.International journal of molecular sciences · 2021
    Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Edward RockensteinUniversity of California, San Diego, Neurosciences Department, La Jolla, CA 92093-0624, USA.
Kiren Ubhi
Edith Doppler
Philipp Novak
Herbert Moessler
Bin Li
Julie Blanchard
Inge Grundke-Iqbal
Khalid Iqbal
Michael Mante
Anthony Adame
Leslie Crews
Eliezer Masliah
University of California, San Diego · USNew York State Office for People With Developmental Disabilities · USEVER Neuro Pharma (Austria) · AT

Funding

VIRUS-INDUCED BRAIN PATHOLOGYP50AG005131 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BREWER, JAMES B · 1985 to 2018
$55.4M
Tissue Culture CoreP01AG022074 · NIA · J. DAVID GLADSTONE INSTITUTES · PI MUCKE, LENNART · 2003 to 2012
$27.0M
Viral VectorsP01AG010435 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TUSZYNSKI, MARK H. · 1991 to 2014
$20.9M
Project 4: A Developmental Perspective to Nitrosative/Oxidative SusceptibilityP01ES016738 · NIEHS · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI LIPTON, STUART A · 2008 to 2012
$8.5M
Project-002P30NS076411 · NINDS · SCINTILLON INSTITUTE FOR PHOTOBIOLOGY · PI LIPTON, STUART A · 2011 to 2016
$4.5M
a-synuclein clearance strategies for the treatment of Lewy body disease.R37AG018440 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MASLIAH, ELIEZER · 2006 to 2014
$2.7M
NIA NIH HHS AG05131NIA NIH HHS P01 AG010435NIA NIH HHS P01 AG022074NIA NIH HHS P50 AG005131NIA NIH HHS R37 AG018440NIEHS NIH HHS P01 ES016738NINDS NIH HHS P30 NS076411
6 · The paper itself

Abstract

Adult neurogenesis, the production of new neurons in certain brain regions, is known to decrease with age and the loss of neurogenic potential has been implicated in Alzheimer's disease (AD), a leading cause of dementia in the elderly. Cerebrolysin (CBL) has been shown to increase neurogenesis in models of stroke and AD. CBL is composed of small peptides with activity similar to neurotrophic factors including ciliary neurotrophic factor (CNTF), which may mediate its neurogenic effects. This study compares the effects of CBL and two peptides with corresponding to an active region of CNTF (Peptide 6 and 6A) across neurogenic brain regions in amyloid-β protein precursor (AβPP) transgenic (tg) mice. Both CBL and Peptides 6 and 6A were able to increase the numbers of neuroblasts (DCX+ cells) and BrdU+ cells in a regionally specific manner across the subventricular zone, olfactory bulb, and hippocampus. The increased generation of new cells and cell survival in animals treated with Peptides 6 and 6A was accompanied by an increase in PCNA+ cells. In contrast, AβPP tg mice treated with CBL displayed reduced levels of TUNEL staining, while levels of PCNA were unaltered. Collectively these results demonstrate that while CBL and Peptides 6 and 6A all potentiate neurogenesis in the AβPP tg mice, their relative modes of action may differ with CBL associated with reduced apoptosis and Peptides 6 and 6A working by augmenting cell proliferation. These results are consistent with a potential therapeutic relevance for Peptides 6 and 6A in AD and other disorders characterized by neurogenic deficits.

Indexed as

Alzheimer DiseaseAmino AcidsAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnimalsBrainBromodeoxyuridineCell DeathCiliary Neurotrophic FactorDisease Models, AnimalDoublecortin Domain ProteinsDoublecortin ProteinGene Expression RegulationHumansIn Situ Nick-End LabelingMiceAmino AcidsAmyloid beta-Peptidesamyloid beta-protein (1-42)Amyloid beta-Protein PrecursorBromodeoxyuridinecerebrolysinCiliary Neurotrophic FactorDCX protein, humanDcx protein, mouseDoublecortin Domain ProteinsDoublecortin ProteinMicrotubule-Associated ProteinsNeuropeptidesPeptide FragmentsPeptidesProliferating Cell Nuclear Antigen

Identifiers

PMID21860085
PMCPMC3925781
OpenAlexW108066784

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.